Slideshow

OSA and Dyslipidemia: Beyond the Obesity Factor

Author(s):

Veronica Hackethal MD

Obstructive sleep apnea negatively impacts lipid levels, greatly increasing risk for CV disease and independent of obesity, according to the largest analysis of the link to date.

Related Videos
Experts' Perspectives: Top Stories in Cardiology for 2024
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
The APAC Recap: Dyslipidemia at CAPP Live 2024 with Viet Le, DMSc, PA-C | Image Credit: APAC
HCPLive Lipoprotein Apheresis Special Report thumbnail
HCPLive Lipoprotein Apheresis Special Report thumbnail
HCPLive Lipoprotein Apheresis Special Report thumbnail
Steve Nissen, MD | Credit: Cleveland Clinic
Related Content
FDA Accepts Plozasiran NDA for Familial Chylomicronemia Syndrome | Image Credit: US Food and Drug Administration
January 20th 2025

FDA Accepts Plozasiran NDA for Familial Chylomicronemia Syndrome

Connor Iapoce
Prof. Kausik Ray: Inclisiran Data at ESC Congress 2020
September 3rd 2020

Prof. Kausik Ray: Inclisiran Data at ESC Congress 2020

Patrick Campbell
Genetic Determinants of LDL-C Inversely Linked to Type 2 Diabetes Risk | Image Credit: Massachusetts General Hospital
January 15th 2025

Genetic Determinants of LDL-C Inversely Linked to Type 2 Diabetes Risk

Connor Iapoce
The State of Preventive Cardiology
August 28th 2020

The State of Preventive Cardiology

Kevin Kunzmann
Bayer Submits Finerenone Application to FDA for Treatment of Heart Failure | Image Credit: US Food and Drug Administration
January 10th 2025

Bayer Submits Finerenone Application to FDA for Treatment of Heart Failure

Connor Iapoce
Polypill Therapy Cost-Effective for CVD Risk in Underserved Populations | Image Credit: Sardar Faizan/Unsplash
January 8th 2025

Polypill Therapy Cost-Effective for CVD Risk in Underserved Populations

Connor Iapoce
© 2025 MJH Life Sciences

All rights reserved.